A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.

Hang Quach; Masa Lasica; David Routledge; Anna Kalff; Andrew Lim; Michael Low; Jane A Estell; M Hasib Sidiqi; Philip Campbell; Richard Wilhelm Eek; Hock C Lai; Georgia J McCaughan; James D'Rozario; Peter Browlett; Rajeev Rajagopal; Jessica Heenan; Nicholas E Murphy; William Renwick; Georgina Huan; Peter Mollee

Conference Proceedings

A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.

Hang Quach, Masa Lasica, David Routledge, Anna Kalff, Andrew Lim, Michael Low, Jane A Estell, M Hasib Sidiqi, Philip Campbell, Richard Wilhelm Eek, Hock C Lai, Georgia J McCaughan, James D'Rozario, Peter Browlett, Rajeev Rajagopal, Jessica Heenan, Nicholas E Murphy, William Renwick, Georgina Huan, Peter Mollee

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

DOI: 10.1200/JCO.2021.39.15_suppl.TPS8055

Abstract

TPS8055 Background: Len maintenance post ASCT is standard of care for patients (pts) with NDMM. Deep responses (CR or better) post ASCT correlates with better progression free survival (PFS). In a meta-analysis of len maintenance post ASCT (McCarthy PL et al. J Clin Oncol. 2017), only 10.7% of pts achieve CR post ASCT, and 72% of pts who discontinued len maintenance did so because of progressive disease (PD). Selinexor is a selective inhibitor of nuclear export that blocks exportin 1, thus retaining tumour suppressor proteins within the nucleus while blocking proto-oncoprotein translation. It is approved in combination with bortezomib and dexamethasone (dex) for pts with MM who have had at ..

View full abstract